FORM 7

MONTHLY PROGRESS REPORT

February 2019

Name of Listed Issuer: Veritas Pharma Inc. (the "Company").

Trading Symbol: VRT

Number of Outstanding Listed Securities: 12,157,398 common shares

Date: March 29, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   On February 8, 2019, the Company consolidated its issued and outstanding share capital on the basis of one postconsolidation share for 10 preconsolidation common shares.

   On February 11, 2019, the Company received investigation license from the Commonwealth of Puerto Rico Medicinal Cannabis Regulatory Board allowing clinical evaluation of Veritas Pharma's lead cannabis product (CTL-X) in alleviating acute pain. IMC and FDI represent two of Puerto Rico's leading researchers in medicinal cannabis. The concession is also the first of its kind, representing the first collaboration of such by local partners and a foreign-owned and publicly traded entity.

   On February 11, 2019, the Company's CEO and director, Dr Lui Franciosi resigned as CEO and director. The Company interim CFP Peter McFadden will fill the executive roles in the interim until a qualified replacement is found.

   On February 12, 2019, the Company entered into an agreement with TG Initiatives Ltd. to purchase a commercial processing facility for hemp and cannabis products.

   On February 21, 2019, the Company's subsidiary, Puerto Rico LLC., has dosed the first adult volunteer in its clinical trial of its lead cannabis product for the treatment of acute pain.

   Please refer to Question 1

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   None.

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   Please refer to Question 1.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   None.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   None.

7. Describe the acquisition of new customers or loss of customers.

   None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   None

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

   None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

    None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    None.

13. Provide details of any securities issued and options or warrants granted.

    Please refer to Question 1.

14. Provide details of any loans to or by Related Persons.

    None.

15. Provide details of any changes in directors, officers or committee members.

    Please refer to Question 1.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

    None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 29, 2019

Nick Standish
Name of Director or Senior Officer

"Nick Standish"
Signature

Director
Official Capacity

Issuer Details Name of Issuer Veritas Pharma Inc.	For Month End February 28, 2019	Date of Report YY/MM/D 2019/03/29
Issuer Address Suite 101 – 2386 East Mall, University of British Columbia, Vancouver, BC V6T 1Z3		
City/Province/Postal Code North Vancouver, BC V7M 3J3	Issuer Fax No.	Issuer Telephone No. (604) 866-3755
Contact Name Nick Standish	Contact Position Director	Contact Telephone No. (604) 866-3755
Contact Email Address nick@nsclglobal.com	Web Site Address www.veritaspharmainc.com	